|
July 2005 |
The combination of verteporfin PDT and triamcinolone is already changing practice patterns.
Specialists discuss how they're using pegaptanib in light of the clinical trial protocol and a possible increase in patient visits.
Opinions vary on the extent we should use these data to guide clinical decision-making.